- Home
- ENB vs ZTS Comparison
ENB vs ZTS Comparison
Compare ENB & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENB | ZTS |
|---|---|---|
| Founded | 1949 | 1952 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.6B | 32.5B |
| IPO Year | 1998 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ENB | ZTS |
|---|---|---|
| Price | $48.22 | $72.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $65.00 | ★ $154.18 |
| AVG Volume (30 Days) | ★ 4.6M | 3.7M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.13% | 1.86% |
| EPS Growth | ★ 37.61 | 10.05 |
| EPS | 1.40 | ★ 3.08 |
| Revenue | ★ $65,194,000,000.00 | $9,467,000,000.00 |
| Revenue This Year | N/A | $5.63 |
| Revenue Next Year | $3.22 | $4.77 |
| P/E Ratio | $35.82 | ★ $23.81 |
| Revenue Growth | ★ 21.92 | 2.28 |
| 52 Week Low | $45.03 | $71.00 |
| 52 Week High | $58.45 | $149.75 |
Technical Indicators
Market Signals| Indicator | ENB | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 30.52 | 41.90 |
| Support Level | $46.24 | $71.24 |
| Resistance Level | $48.28 | $78.74 |
| Average True Range (ATR) | 0.79 | 1.90 |
| MACD | 0.03 | -0.34 |
| Stochastic Oscillator | 5.03 | 13.52 |
Price Performance
Historical ComparisonAbout ENB Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the US and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also operates regulated natural gas utilities in the US and Canada, including Canada's largest natural gas distribution company. The firm has a small renewable energy portfolio primarily focused on onshore and offshore wind projects.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.